Stay updated on Encorafenib Combo With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Encorafenib Combo With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Encorafenib Combo With Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe page shows a new revision tag indicating an update to the site version (v3.6.6) and the previous revision tag (v3.6.5) was removed.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5, indicating a platform-level update. No study content or user-facing details appear to be altered.SummaryDifference0.0%

- Check40 days agoChange DetectedThe page’s revision label was updated to v3.6.4, signaling a software update to the ClinicalTrials.gov page. This update is a backend/UI tweak and does not modify the study details.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision tag updated to v3.6.3, signaling a current version of the page. This update appears to be a metadata/version bump without changes to the study details, locations, or eligibility criteria.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, indicating a software update. No changes to the displayed study information or navigation are evident.SummaryDifference0.0%

- Check83 days agoChange DetectedRecruitment status updated to 'No longer looking for participants'. Added help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study, Intervention/Treatment) and updated the page revision from v3.5.5 to v3.6.0, removing the old Intervention / Treatment heading.SummaryDifference0.4%

Stay in the know with updates to Encorafenib Combo With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Encorafenib Combo With Pembrolizumab in Melanoma Clinical Trial page.